Skip to main content
SpringerLink
Log in

Optimal follow-up of ovarian cancer patients

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Gynecological malignancies account for roughly 10 % of all cancers in women with ovarian cancer as leading cause of death due to gynecological tumors. Surveillance programs of ovarian cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for cure of patient with recurrence. Since there is no prospective, high evidence data on optimal surveillance program after primary treatment of patients with ovarian cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including gynecological examination, still contribute to the greatest number of recurrence detections. Radiologic and laboratory tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed: 6 July 2014.

  2. Salani R, Backes FJ, Fung Kee Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignances: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78. doi:10.1016/j.ajog.2011.03.008.

    Article  PubMed  Google Scholar 

  3. Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol. 2009;71(1):43–52. doi:10.1016/jcritrevonc.2008.12.008.

    Article  PubMed  Google Scholar 

  4. SEER Cancer Statistics Factsheets. Ovary Cancer. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/ovary.html, http://seer.cancer.gov/statfacts/html/ovary.html. Accessed: 26 June 2014.

  5. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: resent advances. Hum Pathol. 2009;40(9):1213–23. doi:10.1016/j.humpath.2009.04.017.

    Article  CAS  PubMed  Google Scholar 

  6. Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6:201. doi:10.1186/1471-2407-6-201.

    Article  PubMed Central  PubMed  Google Scholar 

  7. NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer including Fallopian Tube Cancer and primary peritoneal cancer. Version 3. 2014. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed: 7 Aug 2014.

  8. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;102(3):432–9.

    Article  CAS  PubMed  Google Scholar 

  9. Armstrong DK, Bundy B, Wenzel L, et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

    Article  CAS  PubMed  Google Scholar 

  10. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trial of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2);105–112.

    Article  PubMed  Google Scholar 

  11. Gadducci A, Cosio A, Zola P, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicentre retrospective Italian study. Gynecol Oncol. 2010;116(3):358–63. doi:10.1016/j.ygyno.2009.11.008.

    Article  PubMed  Google Scholar 

  12. Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):307–11. doi:10.1016/j.ygyno.2009.10.074.

    Article  PubMed  Google Scholar 

  13. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  14. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200.

    Article  CAS  PubMed  Google Scholar 

  15. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegyleted liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628–35. doi:10.1200/JCO.2010.33.8566.

    Article  CAS  PubMed  Google Scholar 

  16. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25. doi:10.1200/JCO.2008.19.1684.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374(9698):1331–8. doi:10.1016/S0140–6736(09)61157–0.

    Article  CAS  PubMed  Google Scholar 

  18. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.

    Article  CAS  PubMed  Google Scholar 

  19. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. doi:10.1056/NEJMoa1103799.

    Article  CAS  PubMed  Google Scholar 

  20. Kim A, Ueda Y, Naka T, et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14. doi:10.1186/1756–9966-31–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Palmar MK, Ledermann JA, Columbo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.3 trial. Lancet. 2003;361(9375):2099–106.

    Article  Google Scholar 

  23. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.

    Article  CAS  PubMed  Google Scholar 

  24. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–9. doi:10.1200/JCO.2009.25.7519.25.

    Article  CAS  PubMed  Google Scholar 

  25. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study od recurrent and refractory ovarian cancer. Gynecol Oncol. 2004;95(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  26. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. doi:10.1200/JCO.2007.13.6606.

    Article  CAS  PubMed  Google Scholar 

  27. Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer study group. J Clin Oncol. 2011;29(2):242–8. doi:10.1200/JCO.2009.27.8911.

    Article  CAS  PubMed  Google Scholar 

  28. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. doi:10.1200/JCO.2013.51.4489.

    Article  CAS  PubMed  Google Scholar 

  29. Greer BE, Bundy BN, Ozols RF, et al. Implication of second-look laparotomy in the context of optimally resected stage II ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;99(1):71–9.

    Article  PubMed  Google Scholar 

  30. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol. 2003;30(3):401–12.

    Article  PubMed  Google Scholar 

  31. Santillan A, Gary R, Zuhurak ML, et al. Risk of epithelial ovarian cancer recurrence in patient with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23(36);9338–43.

    Article  PubMed  Google Scholar 

  32. Piovano E, Attamente L, Macchi C, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359–65. doi:10.1097/IGC.0000000000000218.

    Article  PubMed  Google Scholar 

  33. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19(3):367–74. doi:10.1111/IGC.0b013e3181a1cc02.

    Article  PubMed  Google Scholar 

  34. Rustin GJ, van der Burg ME, Griffin C. Early versus delayed treatment of relapsed ovarian cancer (MRC ov05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63. doi:10.1016/S0140-6736(10)61268-8.

    Article  PubMed  Google Scholar 

  35. Rustin GJ. Follow-up with CA 125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011;22(8):viii45–8. doi:10.1093/annonc/mdr471.

  36. Wang F, Ye Y, Xu X, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreductive surgery. J Ovarian Res. 2013;6(1):14. doi:10.1186/1757–2215-6–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Xu X, Chen X, Dai Z, et al. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. J Exp Clin Cancer Res. 2013;32:61. doi:10.1186/1756-9966-32-61.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117(2):336–40. doi:10.1016/j.ygyno.2010.01.014.

    Article  PubMed  Google Scholar 

  39. AGO Study Group. Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOP III). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. https://clinicaltrials.gov/ct2/show/NCT01166737?term=desktop+III&rank=1NLMIdentifier:NCT01166737. Accessed: 7 Aug 2014.

  40. Fehm T, Heller F, Krämer S, et al. Evaluation of CA 125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25(3 A):1551–4.

    PubMed  Google Scholar 

  41. Bhosale P, Peungjesada S, Wei W, et al Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA 125 levels. Int J Gynecol Cancer. 2010;20(6):936–44. doi:10.1111/IGC.0b013e3181e82a7f.

    Article  PubMed  Google Scholar 

  42. Risum S, Hogdall C, Markova E, et al. Influence of 2-(18 F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009;19(4):600–4. doi:10.1111/IGL.0b013e3181e3cc94.

    Article  PubMed  Google Scholar 

  43. Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT scan in suspected recurrent ovarian cancer: a prospective multicentre study as part of the Australian PET Date Collection Project. Gynecol Oncol. 2009;112(2):462–8. doi:10.1016/j.gyno.2008.08.027.

    Article  CAS  PubMed  Google Scholar 

  44. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164–74. doi:10.1016/j.ejrad.2008.02.019.

    Article  PubMed  Google Scholar 

  45. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24 (Suppl 6):vi24–32.

    PubMed  Google Scholar 

  46. Matkovic´ V, Haller H, Vrdoljak E, et al. [Clinical recommendations for diagnosing, treatment and monitoring of patients with ovarian cancer—Croatian Oncology Society and Croatian Society for Gynecology and Obstetrics as Croatian Medical Association units and Croatian Society of Gynecological Oncology]. Lijec Vjesn. 2013;135(9–10):235–41.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Oncology and Radiotherapy, Clinical Hospital Centre Split, Spinčićeva 1, 21000, Split, Croatia

    Eduard Vrdoljak MD, PhD, Branka Petrić Miše MD, Tihana Boraska Jelavić MD, PhD & Ante Strikić MD

  2. Clinic of Pathology, Forensic Medicine and Cytology, Clinical Hospital Centre Split, Spinčićeva 1, 21000, Split, Croatia

    Snježana Tomić MD, PhD & Dinka Šundov MD, PhD

Authors
  1. Eduard Vrdoljak MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Branka Petrić Miše MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tihana Boraska Jelavić MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Snježana Tomić MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dinka Šundov MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ante Strikić MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduard Vrdoljak MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vrdoljak, E., Miše, B., Jelavić, T. et al. Optimal follow-up of ovarian cancer patients. memo 8, 57–61 (2015). https://doi.org/10.1007/s12254-014-0188-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0188-y

Keywords

Search

Navigation